Gregory Conn
Chief Tech/Sci/R&D Officer chez PDS BIOTECHNOLOGY CORPORATION
Fortune : 457 558 $ au 31/03/2024
Profil
Gregory L.
Conn is the founder of PDS Operating Corp.
He is currently the Chief Scientific Officer at PDS Biotechnology Corp.
He previously worked as the Director of the Process Development Department at Covance Biotechnology Services, Inc. from 1998 to 2000.
Dr. Conn holds a graduate and doctorate degree from Albert Einstein College of Medicine, Inc.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
PDS BIOTECHNOLOGY CORP.
0,37% | 05/01/2023 | 115 545 ( 0,37% ) | 457 558 $ | 31/03/2024 |
Postes actifs de Gregory Conn
| Sociétés | Poste | Début |
|---|---|---|
| PDS BIOTECHNOLOGY CORPORATION | Chief Tech/Sci/R&D Officer | 15/03/2019 |
Anciens postes connus de Gregory Conn
| Sociétés | Poste | Fin |
|---|---|---|
Covance Biotechnology Services, Inc.
 Covance Biotechnology Services, Inc. Pharmaceuticals: MajorHealth Technology Covance Biotechnology Services, Inc. develops pharmaceutical products. The company offers two microbiology laboratories, one for mycoplasma analysis, and a second for molecular biology. It provides services to biomolecules, including recombinant proteins, monoclonal antibodies, vaccines, blood products, and gene therapy products. The company was founded by Richard J. Hawkins, V. Bryan Lawlis, and John A. Scarlett in 1995 and is headquartered in Princeton, NJ. | Corporate Officer/Principal | 01/01/2000 |
PDS Operating Corp.
 PDS Operating Corp. BiotechnologyHealth Technology PDS Operating Corp. operates as a biopharmaceutical company. It develops immunotherapies for cancer and infectious disease. The firm’s versamune is capable of potent activation of immune cells without the side effects of traditional vaccines, efficiently delivering disease related antigen targets to the immune system and promoting antigen processing to present antigen appropriately to generate both strong prophylactic and therapeutic immune responses to disease. The company was founded by Frank K. Bedu-Addo and Gregory L. Conn and is headquartered in Princeton, NJ. | Founder | - |
Formation de Gregory Conn
| Albert Einstein College of Medicine, Inc. | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| PDS BIOTECHNOLOGY CORPORATION | Health Technology |
| Entreprise privées | 2 |
|---|---|
PDS Operating Corp.
PDS Operating Corp. BiotechnologyHealth Technology PDS Operating Corp. operates as a biopharmaceutical company. It develops immunotherapies for cancer and infectious disease. The firm’s versamune is capable of potent activation of immune cells without the side effects of traditional vaccines, efficiently delivering disease related antigen targets to the immune system and promoting antigen processing to present antigen appropriately to generate both strong prophylactic and therapeutic immune responses to disease. The company was founded by Frank K. Bedu-Addo and Gregory L. Conn and is headquartered in Princeton, NJ. | Health Technology |
Covance Biotechnology Services, Inc.
Covance Biotechnology Services, Inc. Pharmaceuticals: MajorHealth Technology Covance Biotechnology Services, Inc. develops pharmaceutical products. The company offers two microbiology laboratories, one for mycoplasma analysis, and a second for molecular biology. It provides services to biomolecules, including recombinant proteins, monoclonal antibodies, vaccines, blood products, and gene therapy products. The company was founded by Richard J. Hawkins, V. Bryan Lawlis, and John A. Scarlett in 1995 and is headquartered in Princeton, NJ. | Health Technology |
